polyphosphazene-docetaxel conjugate (Hyundai Bioscience/CNPharm)

N/A

Report date: 2025/03/20 09:18:24
NME

Base Information

Drug Namepolyphosphazene-docetaxel conjugate (Hyundai Bioscience/CNPharm)
Drug Alias NamePolytaxel
ClassificationDiagnostic agent (In vivo)Small molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsPancreatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHyundai Bioscience Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCNPharm Co LtdHyundai Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A